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Abstract
Background: Non-Hodgkin lymphomas are a heterogeneous group of solid tumours that constitute the 5th highest cause of
cancer mortality in the United States and Canada. Poor control of cell death in lymphocytes can lead to autoimmune disease
or cancer, making genes involved in programmed cell death of lymphocytes logical candidate genes for lymphoma
susceptibility.
Materials and Methods: We tested for genetic association with NHL and NHL subtypes, of SNPs in lymphocyte cell death
genes using an established population-based study. 17 candidate genes were chosen based on biological function, with 123
SNPs tested. These included tagSNPs from HapMap and novel SNPs discovered by re-sequencing 47 cases in genes for
which SNP representation was judged to be low. The main analysis, which estimated odds ratios by fitting data to an
additive logistic regression model, used European ancestry samples that passed quality control measures (569 cases and 547
controls). A two-tiered approach for multiple testing correction was used: correction for number of tests within each gene
by permutation-based methodology, followed by correction for the number of genes tested using the false discovery rate.
Results: Variant rs928883, near miR-155, showed an association (OR per A-allele: 2.80 [95% CI: 1.63–4.82]; pF= 0.027) with
marginal zone lymphoma that is significant after correction for multiple testing.
Conclusions: This is the first reported association between a germline polymorphism at a miRNA locus and lymphoma.
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Introduction
Non-Hodgkin lymphoma (NHL) is a collection of different
subtypes, each with different clinical presentation, preferred
treatment regimens and prognosis. These subtypes appear to be
derived from progenitor cells at different stages of B- and T-cell
development. For example, mantle cell lymphomas are derived
from pre-germinal centre B cells while follicular lymphomas arise
from germinal centre B-cells [1]. The development of an active
and specialized lymphocyte requires many steps [2], and each is
controlled by apoptosis. If all requirements to proceed to the next
level of development and activation are not met, lymphocytes
enter a default program and are selected to die by apoptosis. This
commonality interested us in testing the hypothesis that variation
in cell death genes would affect risk of NHL.
Programmed cell death, the best characterized form of which is
apoptosis, gives cells the ability to auto-destruct following specific
triggers. Such triggers can be the presence or absence of a signal,
depending on the cell context. Apoptosis has a central role in the
development of the immune system, balancing the need for an
effective immune response with the need to eliminate auto-reactive
cells [2]. The crucial role of apoptosis in lymphoma was
established by the discovery that the most common translocation
in follicular lymphoma (FL), t(14;18), caused the inappropriate
expression of BCL2 by juxtaposing it to IG regulatory elements [3].
BCL2 is now known to be at the centre of a family of proteins with
roles in apoptosis.
The number of BCL2-homology domains (or BH domains)
determines whether the proteins in this family have anti-apoptotic
or pro-apoptotic roles. Members with 4 BH-domains (BCL2,
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MCL1, and BCL-xL) have anti-apoptotic roles. Both the BH3-
only members (including BIM, PUMA/BBC3, NOXA/PMAIP1,
BID, BAD, BMF, BIK/BLK/NBK, HRK/DP5), which have only
a BH3 domain, and the members with three BH domains (BAX
and BAK) have pro-apoptotic functions [4]. Interactions between
these diverse family members allow cells to respond to a variety of
triggers, such as DNA damage, lack of B-cell receptor signaling
from other cells, environmental toxins, or interleukin withdrawal.
Tumour cells can acquire mutations that inactivate parts of this
signaling network, causing tumourigenesis and drug resistance [5].
Seventeen candidate genes were selected following literature
review and were chosen based on their role in apoptosis in
lymphocyte development: BAX, BCL2, BCL6 [6], BCL10 [7],
BCL2L11, BBC3, BECN1 [8], BMI1 [9], FAS [10], MCL1, MDM2
[11], PMAIP1, RFWD2 [12], SKP2 [13], miR-15a/16 [14], miR-17-
92 [15], and miR-155 [16]. The coverage of known SNPs across
each candidate gene at the time of initiation of the study was
assessed by determining the ratio of the number of known SNPs to
tagSNPs in each gene. 11 genes with low coverage were re-
sequenced in DNA samples from 47 NHL cases. Targeted re-
sequencing provided new, more thorough coverage of genetic
information in candidate genes. SNPs were chosen for genotyping
based on linkage disequilibrium relationships within the re-
sequencing data and based on HapMap data. SNPs selected were
genotyped in 797 cases and 790 controls and tested for association
with risk of common NHL subtypes.
Materials and Methods
Study population
The study population has been previously described [17,18,19]
and is summarized in Table S1. Briefly, all NHL cases diagnosed
in British Columbia from March 2000 to February 2004, residing
in the Greater Vancouver Regional District and Greater Victoria
(Capital Regional District), and aged 20 to 79 were invited to
participate. HIV-positive cases and cases with prior transplant
were excluded. Categorization of ethnicity was based on self-
reported ethnicity of each participant’s four grandparents.
Population controls were identified from the Client Registry of
the British Columbia Ministry of Health and were frequency
matched to cases by sex, age (within 5-year age groups), and area
of residence in an approximate 1:1 ratio. 828 cases and 848
controls completed at least part of a study questionnaire and 797
cases and 790 controls had DNA (Table S1). The study was
approved by the joint University of British Columbia/British
Columbia Cancer Agency Research Ethics Board. Written
informed consent was obtained from all participants.
From the 1587 samples, DNA was derived from whole blood in
407 samples, lymphocytes isolated from blood in 782 samples,
mouthwash in 24 samples and saliva in 48 samples. DNA
extraction was done using the PureGene DNA isolation kit
(Gentra Systems, Minneapolis, MN) following the manufacturer’s
instructions. DNA was quantified using PicoGreen (Molecular
Probes, Invitrogen, Burlington, ON). Samples with limited
amounts of DNA (326/1587 samples) were subjected to whole-
genome amplification using the RepliG kit (QIAGEN, Missis-
sauga, ON, Canada); these are hereafter referred to as ‘‘WGA’’
samples.
Sequencing
Forty-seven NHL case samples (Table S2) were selected for
SNP discovery via Sanger sequencing by a protocol previously
described [20], based on age (preference was given to younger
patients to enrich for genetics-based cases) and DNA quantity.
Genomic sequences for use in primer design were obtained for
each gene using Ensembl, with known SNPs annotated. Primers
were designed using Primer 3 [21]. For all 17 candidate genes,
1.5 kb upstream of each gene’s transcriptional start site was
sequenced to identify genetic variation in promoter sequences near
the gene; a subset of the candidate genes were subject to additional
re-sequencing of all exons.
Genes were chosen for exon re-sequencing based on the depth
of genetic variation already present in HapMap Phase II. For each
gene, boundaries were selected by first capturing the gene with an
extra 1.5 kb of sequence on either side of the gene within the
browser window, and then extending the window boundaries until
at least one more SNP in either direction was captured within the
genomic region displayed. Genotypes were downloaded into
Haploview [22]. Using Tagger [23] within Haploview [22], the
set of tagSNPs required to capture the genotypes with r2 = 0.8 was
calculated. A gene was selected for exon re-sequencing if the ratio
of #SNPs/#tagSNPs was less than 2. A ratio ,2 indicates that
there is less than 2-fold redundancy of tagSNPs in HapMap data,
implying that re-sequencing may reveal as yet untagged variants in
that gene. This cut-off was arbitrarily selected, as it can be
interpreted to mean that, on average, a tagSNP represents at least
one more SNP.
Uniform sequencing conditions were enabled by adding the -
21M13F (TGTAAAACGACGGCCAGT) or M13R (CAG-
GAAACAGCTATGAC) extensions to the 59 ends of the forward
and reverse PCR primers, respectively. Primers and PCR
conditions used are listed in Table S3. PCR reactions were
followed by product cleanup using the Ampure bead system
(Agencourt, Bioscience, Beverly, MA). A 2 uL aliquot of purified
PCR product was cycle sequenced using Big Dye Terminator Mix
V.3 at 1/24 chemistry in a total volume of 4 uL (Applied
Biosystems, Foster City, CA) as described previously [20]. As a
quality control measure, both forward and reverse directions were
sequenced. Variants had to be present in both read directions to
be considered valid. Sequences were assembled and inspected in
Mutation Surveyor v3.24 (SoftGenetics, State College, PA). All
new sequenced variants were deposited in dbSNP.
TagSNP selection
Sequencing results were exported from Mutation Surveyor and
imported into Haploview [22] for tagSNP selection using Tagger
[23]. In addition, publicly available data from HapMap phase II
was obtained as described above. To obtain tagSNPs representing
both in-house re-sequencing data and public data, we used a
strategy similar to one previously described [24]. Briefly, for each
gene, tagSNPs were selected in four stages. We first selected
tagSNPs for the SNPs that were present in both the sequencing
results and the HapMap results, within the sequenced samples,
using r2 = 1 and a minor allele frequency cut-off (MAF) of 2% (set
a). These tagSNPs were then preferentially selected in the next
step, selecting tagSNPs with r2 = 0.8 and MAF$5% in HapMap
samples from SNPs that were present in both the sequencing
results and the HapMap results (set b). Third, tagSNPs were
selected for all the SNPs found by sequencing, using the sequenced
samples and force-including set a, with the same criteria as those
used for set a (to make set c). Last, tagSNPs were selected from
HapMap genotyping results, force-including set b, and using the
same criteria as for set b (making up set d). The final genotyped set
of SNPs was made up of the combination of sets c+d.
Genotyping
The SNPs selected for this study were part of a larger Golden
Gate assay (Illumina, San Diego, CA), which also contained SNPs
Cell Death Genes and NHL Risk
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from candidate genes in other pathways related to other
hypotheses. SNPs predicted to fail assay design (most often due
to being too close together) were replaced when possible by
equivalent tagSNPs. In addition to tagSNPs, 51 ancestry-
informative markers (AIMs) selected from Halder et al. [25] were
included in the assay.
600 ng of each genomic or WGA DNA sample was arrayed into
18 96-well plates and sent to The Centre for Applied Genomics,
the Hospital for Sick Children in Toronto, Canada. The resulting
genotypes were assessed using Genome Studio version 2009.1
(Illumina, San Diego, CA). The first steps in genotype quality
control (Q/C) were performed in Genome Studio; systems and
databases in the laboratory of DD completed the final steps.
Genotypes derived from WGA and genomic DNA were subjected
to Q/C separately.
Data quality control (SNPs)
For all genotypes, a GenCall Score cutoff of 0.25 was used,
following Illumina recommendations for GoldenGate technology.
The following SNPs were excluded: SNPs with GenTrain scores
,0.4; SNPs with GenTrain scores between 0.4 and 0.7 and poor
clustering (unexpected number of clusters, or clusters that were not
well defined); SNPs with more than 3 clusters (which potentially
indicate copy number variants); mono-allelic SNPs; SNPs with any
genotype discrepancies between 53 pairs of duplicate samples;
SNPs with call rate ,95% in any sample type category (blood,
mouthwash or saliva) were excluded for all samples in that
category; one X-chromosome SNP that showed heterozygous calls
in confirmed male samples; and SNPs out of Hardy-Weinberg
equilibrium (p,0.001) in European-ancestry controls.
Of 178 tagSNPs selected for genotyping; 28/178 failed in the
design phase, leaving 150 SNPs ordered for genotyping. Twenty-
seven SNPs were excluded at the genotype quality control stage
(12 SNPs were rejected by the genotyping centre upon initial
inspection, 2 for low GenTrain scores, 5 for being potential copy
number variants, 3 for being monoallelic, 3 for having a call rate
,0.95, and 2 for having 1 error between duplicate genotypes). An
additional 16 SNPs failed quality control only in WGA samples (7
for low GenTrain score and 9 for call rate ,0.95), and 2 SNPs
failed Q/C only in mouthwash or saliva samples. This left 123
SNPs (82%), listed in Table S4, for analysis in all non-WGA
samples and 107 SNPs in both blood and WGA samples.
Data quality control (samples)
WGA samples give different genotype intensities than non-
WGA samples [26] and so were examined separately. SNPs were
excluded from analysis in WGA samples only if they passed the
above criteria but showed any discrepancies in genotype between
52 pairs of WGA sample and matched pre-WGA samples.
Samples with sex discrepancies (Qu et al., in press at Frontiers in
Statistical Genetics and Methodology) were excluded as they could have
been subject to sample swaps during processing, as well as samples
with call rate ,0.98.
DNA samples from 1587 individuals were genotyped, 326/1587
being WGA samples. 58 non-WGA samples and 115 WGA
samples were removed during quality control (23 non-WGA and 1
WGA sample due to gender discrepancies, and 35 non-WGA and
114 WGA samples due to call rate below 98%), leaving 1203 non-
WGA samples+211 WGA samples, or 1414 samples in total.
45/51 AIMs passed quality control. Using genomic controls
methodology, which has been shown to be appropriate when a
modest number of candidate genes are assessed [27,28,29], we
found no evidence for population stratification. The calculated
inflation factor estimate was l=1.0.
Self reported ethnicities were confirmed using identity by state
allele sharing and Multi-Dimensional Scaling (MDS) plots using
HapMap data as the reference. These analyses identified two
previously unidentified sets of sib-pairs, and three individuals who
self-identified as Asian but clustered close to the HapMap CEU
reference cluster. Sib-pair relationships were subsequently con-
firmed after review of study records; the youngest sibling of each
pair (both were non-WGA samples) was excluded from analyses,
as excess relatedness within a group of cases is not appropriate for
a population-based association study. For the three subjects whose
self-reported ethnicity was Asian, a review of study records
indicated one subject self-reported being of Chinese ancestry, and
two self-reported as being of Iranian descent. The subject of
Chinese descent (non-WGA sample) was removed from the
analyses due to concerns of a possible sample swap; and for the
two subjects of Iranian descent the ethnicity was changed to
‘‘other’’. This left 1200 non-WGA samples and 211 WGA
samples, or 1411 samples in total (Table 1).
After all quality control, 1116/1411 samples (569 cases and 547
controls) of European ancestry were included in statistical analysis.
Statistical analysis
Statistical analysis was performed using SVS Suite 7 (Golden
Helix, Bozeman, MT). Logistic regressions under an additive
model were fit for diffuse large B-cell lymphoma (DLBCL),
follicular lymphoma (FL), marginal zone lymphoma (MZL),
mantle cell lymphoma (MCL), all B-cell NHLs and all T-cell
NHLs. In all subtype analyses, selected cases were compared to all
controls. European-ancestry samples were used for analysis; other
ethnicities (Asian, south-east Asian and ‘‘other’’) were tested only
for SNPs that showed association in European-ancestry samples.
For each SNP, we calculated p-values for the model including the
SNP of interest vs. the basic model (which accounted for 5-year
age groups, sex, and region of residence). To test for genetic
interaction between SNPs (in this example SNP A and SNP B), we
tested a logistic regression model including an interaction term
SNPA*SNPB against a model including the effects of SNP A, SNP
B, 5-year age groups, sex and region of residence, limiting the
analysis to European-ancestry samples.
To correct for multiple testing within each gene, full scan
permutation carried out in SVS (10,000 permutations) [30], gave
an adjusted p-value (denoted here by pp). For each permutation,
the program randomly assigns case status to genotypes and
calculates the number of times a more extreme p-value could be
found by chance in permutations of all SNPs in the set. This
method is similarly conservative to Bonferroni adjustment [30].
Like other lymphoma genetic epidemiology researchers [31,32],
we have used a two-tiered approach to multiple testing correction.
The smallest adjusted p-value of SNPs within each gene was taken
to represent the gene, and then the Benjamini-Hochberg
procedure [33], implemented in R version 2.11.1, was applied to
control the false-discovery rate (FDR) across the 17 genes and
obtain a corrected p-value (pF). Adjusted p-values,0.05 were
considered statistically significant. No multiple-testing correction
was implemented for the few genetic interaction tests.
Results
Re-sequencing for SNP discovery
Table 2 lists the candidate genes. Eleven of the 17 genes were
selected for re-sequencing in 47 samples because they failed the
criterion of #SNPs/#tagSNPs.2. Genes ranged from having a
complete lack of genotyped SNPs in HapMap (for example the
10 kb gene BMI1) to densely genotyped genes such as RFWD2
Cell Death Genes and NHL Risk
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(which had 228 SNPs in HapMap and a #SNPs/#tagSNPs ratio
of 7.9) (Table 2). Re-sequencing yielded 155 single nucleotide
variants (Table S5), of which 40% was previously reported in
dbSNP (build 127). Small insertions/deletions were as common as
SNPs (40% vs. 39%, respectively). If one was to look only at
relatively common SNPs (i.e. minor allele frequency (MAF) $5%),
72% of variants observed were previously reported at the time the
sequencing results were analyzed, showing that most of the new
information gathered by re-sequencing lay in rare variants. Eighty-
eight tagSNPs were needed to capture the in-house sequencing
data at r2 = 1, with the exception of singletons which were not
included in the next phase of this study. An r2 of 1 was selected as
the genetic information gained from sequencing was potentially
more relevant because it was derived from lymphoma patient
samples. Only 19/88 of these tagSNPs overlapped with tagSNPs
used to capture the HapMap data, indicating that the information
obtained is non-redundant with that in online databases and that
the additional in-house sequencing produced novel genetic
information valuable for representing (tagging) genetic variation
in some of the candidate genes.
Association results
For a summary of all analysis results see Table 3. One SNP
showed an association that was strong enough to survive multiple
testing correction both at the individual gene and multi-gene level.
rs928883 (close to miR-155) was significantly associated with
marginal zone lymphoma (OR: 2.80 [95% CI: 1.63–4.82];
pp=0.0016; pF=0.0272). rs2829803, located 4 kb away from
rs928883 (r2 = 0.41 between rs2829803 and rs928883), showed a
weaker association with this same subtype (OR: 1.85 [95% CI:
1.12–3.08]). These associations were restricted to European
ancestry samples, as there was no statistically-significant associa-
tion in Asian samples or in South-Asian ancestry samples,
although the power to detect such association was quite low in
these smaller sample sets.
Four other results indicated an association when the permuted
p-values for correction within the gene were used (i.e. pp,0.05),
but did not have pF,0.05. The SNP rs17041883 in BCL2L11 for
marginal zone lymphoma (OR: 0.29 [95% CI: 0.10–0.81];
pp=0.033; pF=0.280), rs6676805 in RFWD2 for mantle cell
lymphoma (OR: 2.05 [95% CI: 1.22–3.45]; pp=0.048;
pF=0.823), rs17642969 close to mir17-92 for T-cell lymphoma
(OR: 0.409 [95% CI: 0.15–1.14]; pp=0.047; pF=0.800), and
rs10512488 in BECN1 for diffuse large B-cell lymphoma (OR: 1.36
[95% CI: 1.03–1.80]; pp=0.034; pF=0.578).
miR-155 has many known targets, including p53BP1 (the
product of TP53BP1), AID (the product of AICDA) and AGTR1
[34]. We had genotypes for 4, 3 and 1 tagSNPs, respectively, for
these genes, in this same sample set. These tagSNPs were selected
using HapMap Phase II genotypes in the CEU population
(r2 = 0.8) for another study in our laboratory. We tested for
interaction of each of these eight SNPs with rs928883. None of
these eight SNPs were significantly associated with MZL.
However, we found evidence for interactions of rs928883 near
miR-155 with rs714629 (p=0.048) and rs9971686 (p=0.051) in
AICDA (interactions odds ratios are tabulated in Table S7). These
two SNPs in AICDA are not in linkage disequilibrium with each
other (r2 = 0).
Discussion
Association studies are often based on tagSNPs, which are
usually selected from HapMap. TagSNPs derived from HapMap
have been identified as non-transferable between populations in
some cases [35] but transferable in others [36], particularly if
tagSNPs are collected from different populations and merged to
create a ‘‘cosmopolitan’’ set [36]. Our re-sequencing strategy, in
which genes showing low redundancy of SNPs in HapMap were
re-sequenced in individuals derived from the population of
interest, ensures good representation of genetic variation in our
genes of interest in these experiments. We note that between the
time of sequencing and publication, continued activity in the
sequencing of human genomes further populated databases; 33%
of SNPs that were not reported in dbSNP build 127 are now in this
public database (build 132).
rs928883, which is associated with MZL in our study, is located
2.3 kb upstream of MIRN155, in the second intron of
MIRN155HG, the host gene of this 64 bp microRNA. It is in
weak LD (r2 of 0.37) with rs2829803, another SNP weakly
associated with MZL. Replication of these findings is needed to
Table 1. Characteristics of samples used in genetic
association analysis.
Cases (%) Controls (%)
Gender
Male 416 (58%) 360 (52%)
Female 301 (42%) 334 (48%)
Age group (years)
20–49 131 (18%) 172 (25%)
50–59 173 (24%) 153 (22%)
60–69 196 (27%) 185 (27%)
70+ 217 (30%) 184 (27%)
Ethnicity
Caucasian 569 (79%) 547 (79%)
Asian 66 (9%) 69 (10%)
South Asian 26 (4%) 31 (4%)
Mixed/Other 33 (5%) 29 (4%)
Unknown/Refused 23 (3%) 18 (2%)
Pathology
B-cell lymphomas
DLBCL 189 (26%) -
FL 205 (29%) -
MZL/MALT 78 (11%) -
MCL 43 (6%) -
SLL/CLL 39 (5%) -
LPL 40 (6%) -
MISC BCL 54 (8%) -
T-cell lymphomas
MF 38 (5%) -
PTCL 24 (3%) -
MISC TCL 7 (1%) -
Total 717 (100%) 694 (100%)
DLBCL =Diffuse Large B-Cell Lymphoma, FL = Follicular Lymphoma, MZ/
MALT =Marginal Zone lymphoma/Mucosa-Associated Lymphoma Tissue
lymphoma, MCL =Mantle Cell lymphoma, SLL = Small Lymphocytic Lymphoma,
LPL = Lymphoplasmacytic Lymphoma, Misc. B-cell =Miscellaneous B-cell
lymphoma, MF =Mycosis Fungoides, PTCL = Peripheral T-Cell Lymphoma, Misc.
T-cell =Miscellaneous T-cell lymphoma.
doi:10.1371/journal.pone.0031560.t001
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Table 3. Summary of results for the top-ranked SNP (ranked by pp) in each gene in European-ancestry samples for the major
subtypes of non-Hodgkin lymphoma (SNP: odds ratio for additive model).
DLBCL (n =148) FL (n =165) MZL/MALT (N=55) MCL (n =40) All B-cell (n =523)
All T-cell
(n = 45)
BAX rs4645900: 0.62 rs4645900: 0.73 rs704243: 1.34 rs704243: 1.66 rs4645900: 0.66 rs11667229: 0.73
BCL2 rs4987873: 0.48 rs1026825: 1.35 rs1564483: 1.85 rs7226979: 1.37 rs4987852: 1.44 rs1801018: 0.57
BCL6 rs1474326: 1.30 BCL6_x10(3083)_A/T: 1.72 rs1474326: 0.86 rs2229362: 0.50 rs3733017: 1.34 rs1523474: 1.23
BCL10 rs12134420: 0.91 rs4949928: 1.25 rs4949927: 1.24 rs4949927: 1.63 rs4949928: 1.17 rs12134420: 1.19
BCL2L11 rs3761704: 1.25 rs10204044: 0.87 rs17041883:0.29* rs17041868: 0.46 rs10204044: 0.89 rs17041868: 0.54
BBC3 rs45474992: 0.54 rs45474992: 0.68 rs884171: 0.90 rs45474992: 0.65 rs45474992: 0.66 rs884171: 0.73
BECN1 rs10512488: 1.36* rs10512488: 0.93 rs10512488: 1.38 rs10512488: 1.52 rs10512488: 1.13 rs10512488: 1.16
BMI1 BMI1_UPSTR(-809)_C/T:
1.55
BMI1_UPSTR(-809)_C/T: 1.04BMI1_UPSTR(-809)_C/T:
1.23
BMI1_UPSTR(-809)_C/T:
0.53
BMI1_UPSTR(-809)_C/T: 1.27 rs985000: 0.49
FAS rs9658761: 1.34 rs2147420: 0.81 rs983751: 0.62 rs2147420: 0.69 rs978522: 1.19 rs9658761: 1.61
MCL1 rs6655975: 1.40 rs6655975: 0.77 rs35392872: 0.47 rs35392872: 0.59 rs35661734: 1.82 rs35661734: 2.63
MDM2 rs1695144: 0.45 rs769412: 0.68 rs3730536: 1.14 rs1695147: 1.41 rs769412: 0.85 rs937283: 1.45
PMAIP1 rs1041978: 1.22 rs1041978: 1.53 rs9957673: 0.67 rs1041978: 1.84 rs1041978: 1.35 rs1041978: 1.42
RFWD2 rs11587785: 1.27 rs12738115: 0.63 rs12738115: 0.63 rs6676805: 2.05* RFWD2_UPSTR(-184)_C/G:
0.70
11587785: 2.37
SKP2 rs3804439: 0.82 rs2362973: 1.2 rs:17279275: 0.63 rs:17279275: 0.61 rs4440390: 1.16 rs10071838: 0.63
MIR15A rs9535416: 0.81 rs9535416: 1.05 rs9535416: 0.71 rs2476391: 0.33 rs9535416: 0.91 rs2476391: 1.11
MIR1792 rs17642969: 0.89 rs17642969: 0.98 rs17642969: 0.74 rs17642969: 0.85 rs17642969: 1.03 rs17642969: 0.41*
MIR155 rs2829803: 0.87 rs928883: 1.35 rs928883: 2.80*‘ rs2829803: 0.78 rs928883: 1.30 ( rs2829803: 1.61
All analyses are done against 547 European-ancestry controls.
*: pp,0.05,
‘: pf,0.05. All p-values and number of samples in each category are listed in Table S6.
DLBCL: Diffuse Large B-Cell Lymphoma, FL: Follicular Lymphoma, MZ/MALT: Marginal Zone lymphoma/Mucosa-Associated Lymphoma Tissue lymphoma, MCL: Mantle
Cell lymphoma.
doi:10.1371/journal.pone.0031560.t003
Table 2. Candidate genes.
Candidate Gene #HapMap SNPs/#tagSNPs1 # novel SNPs found by re-sequencing2 # SNPs genotyped # SNPs analyzed
BAX 1.40 4 8 7
BCL2 2.76 0 21 21
BCL6 1.54 12 12 11
BCL10 2.25 2 9 7
BCL2L11 2.46 1 11 7
BBC3 1.00 11 7 3
BECN1 1.00 3 2 1
BMI1 * 13 2 2
FAS 3.14 9 17 14
MCL1 1.00 7 11 7
MDM2 1.64 8 8 7
PMAIP1 1.00 9 9 6
RFWD2 7.86 6 10 10
SKP2 2.90 1 14 11
MIR15A * 2 3 3
MIR1792 * 4 3 1
MIR155 * 0 3 3
*No SNPs were reported in HapMap.
1Genes with ratio .2 are marked in bold and only had upstream regions re-sequenced.
2Novel SNPs defined as not present in dbSNP build 127.
doi:10.1371/journal.pone.0031560.t002
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validate the results, as our analysis used a relatively small group of
78 MZL samples.
The Em-myc/miR-155 double hit mouse [37], which overex-
presses both myc and miR-155, has an enlarged spleen, a decrease
in white blood cells and high grade malignant lymphomas that are
similar to human acute lymphoblastic leukemia or lymphoblastic
lymphoma, beginning at 6 months of age. miR-155 targets p53BP1
(p53-binding protein 1) [38], AID (activation-induced cytidines
deaminase) [39], AGTR1 [34], and other genes. Known miR-155-
targets are important players in lymphocyte development, marking
miR-155 as an important connection point between these
pathways.
miRNAs are ,22 nucleotide RNAs that act as negative post-
transcriptional regulators of gene expression by binding to
imperfectly complementary sites on target mRNAs. 50% of
miRNA genes are located in fragile sites or cancer-associated
genomic regions [40], as well as being drastically reprogrammed in
cancer and leukemia by copy number variation and differential
expression [41]. Because miRNAs are short and highly conserved,
mutations within miRNAs are expected to be uncommon.
Consistent with this expectation, we found no polymorphisms in
the transcribed region of the three miRNAs studied. Changes in
allele frequencies of the SNPs located in miRNA target sites are
potentially associated with human cancers [42]. In the past year, a
few studies have explored the role of germline variants in
microRNAs (particularly miR-146a, miR-196a and miR-499) in
susceptibility to a variety of epithelial cancers, both familial [43]
and sporadic – with both positive [44,45] and negative reports
[46,47]. To our knowledge, however, no reports of tagSNPs or
other SNPs near microRNAs affecting susceptibility to lymphoma
or subtypes have been published thus far.
Although little is known about the role of miR-155 in MZL, its
role has been investigated in other subtypes of NHL. High miR-
155 expression is a marker of poor prognosis in HL and DLBCL
[48], particularly in activated B-cell type DLBCL [49]. Its roles in
modulation of cytokine production and AID regulation allow it to
regulate the germinal centre response. Suppression of miR-155 in
EBV-infected cells impedes entry into S phase and causes an
increase in apoptosis [50]. The functions miR-155 has in
lymphocytes and its documented effects in lymphoma certainly
make it an interesting candidate gene for further study. As the
causal variant may be another SNP in LD with rs928883, testing
other variants in LD with this SNP could help to identify a variant
that could affect miR-155’s ability to repress its target mRNAs.
Morton et al. [31] examined risk of NHL with BCL10, BCL2L11,
BCL2, BAX and BCL6 and found associations of BCL2L11 with FL,
of BCL6 with DLBCL and BCL2 with MZL. Although we
genotyped SNPs that either overlapped or were in high LD with
these SNPs (r2.0.9), we did not replicate their findings. Two SNPs
in BCL2L11 previously reported to be associated with NHL by
Kelly et al. [32], with one SNP associated with all NHL and the
other also associated with CLL/SLL and FL in particular, were
also genotyped and we were unable to replicate these results.
rs4934436 in FAS, previously associated with NHL risk by Wang
et al. [51], particularly with the DLBCL and FL subtypes, was not
tagged at sufficiently high LD (r2 = 0.6 with the haplotype CGG in
the SNPs rs2234978/rs2147420/rs1571013, genotyped in this
study) to test for replication. rs1056932 in BCL6 was previously
found to be associated with NHL, B-cell lymphomas and T-cell
lymphomas [52]. This SNP was genotyped but did not show
association with any NHL subtype tested. We examined SNPs in
LD with rs2279744 (‘‘SNP 309’’) in MDM2, in female cases of
DLBCL as suggested by Bond et al. [53] but found no association.
Previous reports of no association with NHL risk with variants in
BCL2 [31,54,55], BCL6 [56,57], BCL10 [31,58], BAX [31,54], FAS
[59], and MDM2 [60,61,62] are consistent with our negative
findings. With the exception of the findings of Morton et al. [31]
(which, based on our smaller sample size after quality control
measures are applied, we had ,80% power to replicate) and the
association reported by Wang et al. [51] (for which the SNP was
not adequately tagged in our study), our lack of replication of the
other reported associations may be due to differences between
populations, or could indicate false positive associations in those
studies, as our study did have .80% power to replicate the
reported associations.
Some studies have found that further classifying DLBCLs
according to cell-of-origin subtypes Germinal-Centre B-cell like
(GCB) and Activated B-Cell like (ABC) can clarify associations; for
example, rs80031434 (G397C) was associated only with the GCB
subtype of DLBCL [63]. We do not have comprehensive ABC and
GCB classifications for our samples, however, and are unable to
address this question. Another limitation of our study is the small
number of cases for some NHL subtypes, particularly when
analyzing non-European ethnicities. Finally, a large number of
comparisons have been conducted and, while our multiple-testing
correction methods are conservative, this nevertheless affects the
power of this study.
In summary, we report an association for rs928883, located
near miR-155, with marginal zone lymphoma. To our knowledge
this is the first reported association between germline polymor-
phisms involving a miRNA gene and lymphoma, though the
relevance of microRNAs to cancer in general is well established.
We were not able to replicate some previously reported
associations of SNPs in other apoptosis genes with subtypes of
NHL. Replication of our finding in other studies is needed to
confirm its significance.
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